Gateway Investment Advisers LLC raised its stake in Pfizer Inc. (NYSE: PFE – Get Rating) by 1.7% in the first quarter, according to the company in its last submission to the SEC. The institutional investor owned 1,699,209 shares of the biopharmaceutical company after buying an additional 27,910 shares during the quarter. Pfizer represents about 0.9% of Gateway Investment Advisers LLC’s investment portfolio, making the shares the 20th largest holding company. Pfizer’s Gateway Investment Advisers LLC held $ 87,968,000 at the end of the most recent reporting period.
A number of other large investors have also recently added or reduced their stakes in PFE. Baltimore Washington Financial Advisors Inc. bought a new stake in Pfizer in the fourth quarter worth approximately $ 290,000. PYA Waltman Capital LLC bought a new stake in Pfizer in the fourth quarter worth approximately $ 31,000. Econ Financial Services Corp. bought a new stake in Pfizer in the fourth quarter worth approximately $ 31,000. Rinkey Investments bought a new stake in Pfizer in the fourth quarter worth approximately $ 32,000. Finally, Bivin & Associates Inc. bought a new stake in Pfizer in the fourth quarter worth approximately $ 37,000. Institutional investors and hedge funds own 66.50% of the company’s shares.
In related news, Senior Vice President Jennifer B. Damiko sold 4,218 shares of the business shares in a deal on Tuesday (June 7th). The shares were sold at an average price of $ 53.96, for a total value of $ 227,603.28. Following the sale, the senior vice president now owns 10,846 shares in the company worth $ 585,250.16. The sale was revealed in a document submitted to the Securities and Exchange Commission, which is available on the SEC website. Also, EVP William R. Karapezzi Jr. sold 32,908 shares of the business shares in a deal on Thursday, May 12th. The shares were sold at an average price of $ 50.00 for a total transaction of $ 1,645,400.00. Following the completion of the sale, the executive vice president now owns 38,146 shares of the company worth approximately $ 1,907,300. The disclosure for this sale can be found here. In the last three months, insiders sold 41,126 shares of the company worth $ 2,075,003. Insiders own 0.05% of the company’s shares.
A number of research firms have recently published reports on PFE. StockNews.com raised Pfizer shares from a “buy” rating to a “strong buy” rating in a report on Tuesday, April 19. Goldman Sachs Group set a price of $ 51.00 for Pfizer shares in a report on Wednesday, May 25. Wells Fargo & Company lowered its target for Pfizer stock prices from $ 60.00 to $ 55.00 in a report on Wednesday, May 4. Berenberg Bank set a price of $ 50.00 for Pfizer shares in a report on Friday, May 27. Finally, Barclays set a price of $ 52.00 for Pfizer shares in a report on Tuesday, May 17. Nine stock research analysts rated the shares with a hold rating, ten gave a buy rating and one assigned a strong rating to buy the company’s shares. According to MarketBeat.com, Pfizer has a consensus “Moderate Buying” rating and an average target price of $ 57.26.
Shares of PFE opened at $ 51.59 on Friday. Pfizer Inc. has a one-year low of $ 38.82 and a one-year high of $ 61.71. The company’s 50-day moving average is $ 50.48, and its 200-day moving average is $ 52.21. The company has a debt-to-equity ratio of 0.43, a fast ratio of 1.13 and a current ratio of 1.39. The company has a market capitalization of $ 289.47 billion, a PE ratio of 11.83, a price-earnings-growth ratio of 0.61 and a beta of 0.76.
Pfizer (NYSE: PFE – Get Rating) last released its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $ 1.62 EPS for the quarter, lacking a consensus estimate of $ 1.66 s ($ 0.04). Pfizer had a return on equity of 38.29% and a net profit of 26.97%. The company had revenue of $ 25.66 billion in the quarter, compared to analysts’ expectations of $ 24.73 billion. During the same period last year, the company reported $ 0.93 EPS. Pfizer’s quarterly revenue increased 76.8 percent from the same quarter last year. On average, research analysts predict that Pfizer Inc. will report EPS of 6.61 for the current fiscal year.
The business also recently announced a three-month dividend, which will be paid on Tuesday, September 6. The record shareholders on Wednesday, June 29, will receive a dividend of $ 0.40. This represents a $ 1.60 annual dividend and a dividend yield of 3.10%. The date of the former dividend is Thursday, July 28. Pfizer’s dividend payout ratio (DPR) is currently 36.70%.
Pfizer Company Profile (Get a rating)
Pfizer Inc. discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. Offers drugs and vaccines in a variety of therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin and Eliquis brands; organic products, small molecules, immunotherapies and biosimilar products under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs and oral treatment of COVID-19 under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.
Want to see what other hedge funds hold PFE? Visit HoldingsChannel.com to receive the latest 13F requests and internal deals for Pfizer Inc. (NYSE: PFE – Get rating).
Receive news and reviews for Pfizer Daily – Enter your email address below to receive a brief daily summary of the latest news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.